Megan Othus

Sep 4, 2024 | digitalcommons.library.tmc.edu | Megan Othus |Guillermo Garcia-Manero |John Godwin |James K Weick

Home > UTHealth > GSBS > Journal Articles > 840 Humans, Hematopoietic Stem Cell Transplantation, Induction Chemotherapy, Leukemia, Myeloid, Acute, Recurrence, Remission Induction, Treatment Outcome, Middle Aged, Aged DOWNLOADS Included in Bioinformatics Commons, Biomedical Informatics Commons, Hematology Commons, Hemic and Lymphatic Diseases Commons, Medical Sciences Commons, Oncology Commons COinS...

Jun 3, 2024 | nature.com | Michelle Zhang |Megan Othus |Guillermo Garcia-Manero |John Pagel

AbstractThere has been ongoing debate on the association between obesity and outcomes in acute myeloid leukemia (AML). Currently few studies have stratified outcomes by class I obesity, class II obesity, and class III obesity, and a more nuanced understanding is becoming increasingly important with the rising prevalence of obesity. We examined the association between body mass index (BMI) and outcomes in previously untreated AML in younger patients (age ≤60) enrolled in SWOG S1203 (n = 729).

Jan 23, 2024 | nature.com | Jacob Appelbaum |Ing S. Tiong |Stephen B. Ting |Richard Stone |Guillermo Garcia-Manero |Guido Marcucci | +4 more

This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 251,40 € per year only 20,95 € per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout Data availability For original, de-identified data and/or computer code (R) for analyses please contact the corresponding author ([email protected])....

Nov 7, 2023 | nature.com | Guillermo Garcia-Manero |Nikolai A. Podoltsev |Megan Othus |John Pagel |David A. Rizzieri |Guido Marcucci | +7 more

AbstractPrior experience indicated that use of higher doses of cytarabine during induction for acute myeloid leukemia (AML) with a histone deacetylase inhibitor resulted in high response rates. S1203 was a randomized multicenter trial for previously untreated patients aged 18–60 with AML which compared daunorubicin and cytarabine (DA), idarubicin with higher dose cytarabine (IA) and IA with vorinostat (IA + V). The primary endpoint was event free survival (EFS).